ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 715
2 682
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
ASKA Pharmaceutical Holdings Co Ltd
ASKA Pharmaceutical Holdings Co Ltd
Cost of Revenue
ASKA Pharmaceutical Holdings Co Ltd
Cost of Revenue Peer Comparison
4502
4568
4578
4519
4503
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
|
Cost of Revenue
-¥32.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.5T
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥416.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥639.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥337.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥383.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
See Also
What is ASKA Pharmaceutical Holdings Co Ltd's Cost of Revenue?
Cost of Revenue
-32.2B
JPY
Based on the financial report for Mar 31, 2024, ASKA Pharmaceutical Holdings Co Ltd's Cost of Revenue amounts to -32.2B JPY.
What is ASKA Pharmaceutical Holdings Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-3%
Over the last year, the Cost of Revenue growth was -1%. The average annual Cost of Revenue growth rates for ASKA Pharmaceutical Holdings Co Ltd have been -3% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
